Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: An Eastern Cooperative Oncology Group Study

John P. Hoffman*, Stuart Lipsitz, Thomas Pisansky, James L. Weese, Lawrence Solin, Al B. Benson

*Corresponding author for this work

Research output: Contribution to journalArticle

312 Citations (Scopus)

Abstract

Purpose: A prospective, multiinstitutional trial was initiated in 1991 to examine the tolerance to and efficacy of a program of preoperative chemotherapy (CTRT) and surgical resection for patients with localized adenocarcinoma of the pancreas. Patients and Methods: Fifty-three patients were assessable for analysis, with a median follow-up of 52 months for survivors. Radiation therapy (RT) totaling 5,040 cGy in 180 cGy fractions with mitomycin 10 mg/m2 day 2 and flourouracil (5-FU) 1,000 mg/m2/d continuous infusion days 2 through 5 and 29 through 32 were given as preoperative adjuvant therapy. Twelve patients did not proceed to surgery (one death, one toxicity, three local progression, six distant metastases, one intercurrent illness), whereas 41 patients underwent surgery. Of these, 17 patients did not have resection (11, hepatic and/or peritoneal metastases and six local extension that precluded resection). Twenty-four patients had tumor resection (19 Whipple, four total pancreatectomy, one distal pancreatectomy). Results: Treatment toxicity was primarily hematologic, although a comparable number suffered biliary tract complications, either from obstruction or cholangitis as a result of an occluded stent or the primary tumor. There was one postoperative death. Median survival for the entire group and for the 24 patients with resection was 9.7 and 15.7 months. This survival rate reflected the advanced state of most resected cancers (positive peritoneal cytology, three patients; margins within 2 mm, 13 patients; involved lymph nodes, four patients; and need for superior mesenteric vein (SMV) resection, four patients). Tumor progression was most frequent at metastatic sites. Conclusion: This preoperative CTRT protocol was feasible and safe in a cooperative group setting. Entry of patients with advanced tumors probably accounted for the suboptimal resectability and survival results.

Original languageEnglish (US)
Pages (from-to)317-323
Number of pages7
JournalJournal of Clinical Oncology
Volume16
Issue number1
DOIs
StatePublished - Jan 1 1998

Fingerprint

Pancreas
Adenocarcinoma
Radiotherapy
Drug Therapy
Pancreatectomy
Neoplasms
Neoplasm Metastasis
Mesenteric Veins
Cholangitis
Survival
Biliary Tract
Mitomycin
Fluorouracil
Stents
Cell Biology
Survivors
Survival Rate
Lymph Nodes
Liver

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{27d8ccad4eb4418e96aab9f8b1eb1e9e,
title = "Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: An Eastern Cooperative Oncology Group Study",
abstract = "Purpose: A prospective, multiinstitutional trial was initiated in 1991 to examine the tolerance to and efficacy of a program of preoperative chemotherapy (CTRT) and surgical resection for patients with localized adenocarcinoma of the pancreas. Patients and Methods: Fifty-three patients were assessable for analysis, with a median follow-up of 52 months for survivors. Radiation therapy (RT) totaling 5,040 cGy in 180 cGy fractions with mitomycin 10 mg/m2 day 2 and flourouracil (5-FU) 1,000 mg/m2/d continuous infusion days 2 through 5 and 29 through 32 were given as preoperative adjuvant therapy. Twelve patients did not proceed to surgery (one death, one toxicity, three local progression, six distant metastases, one intercurrent illness), whereas 41 patients underwent surgery. Of these, 17 patients did not have resection (11, hepatic and/or peritoneal metastases and six local extension that precluded resection). Twenty-four patients had tumor resection (19 Whipple, four total pancreatectomy, one distal pancreatectomy). Results: Treatment toxicity was primarily hematologic, although a comparable number suffered biliary tract complications, either from obstruction or cholangitis as a result of an occluded stent or the primary tumor. There was one postoperative death. Median survival for the entire group and for the 24 patients with resection was 9.7 and 15.7 months. This survival rate reflected the advanced state of most resected cancers (positive peritoneal cytology, three patients; margins within 2 mm, 13 patients; involved lymph nodes, four patients; and need for superior mesenteric vein (SMV) resection, four patients). Tumor progression was most frequent at metastatic sites. Conclusion: This preoperative CTRT protocol was feasible and safe in a cooperative group setting. Entry of patients with advanced tumors probably accounted for the suboptimal resectability and survival results.",
author = "Hoffman, {John P.} and Stuart Lipsitz and Thomas Pisansky and Weese, {James L.} and Lawrence Solin and Benson, {Al B.}",
year = "1998",
month = "1",
day = "1",
doi = "10.1200/JCO.1998.16.1.317",
language = "English (US)",
volume = "16",
pages = "317--323",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas : An Eastern Cooperative Oncology Group Study. / Hoffman, John P.; Lipsitz, Stuart; Pisansky, Thomas; Weese, James L.; Solin, Lawrence; Benson, Al B.

In: Journal of Clinical Oncology, Vol. 16, No. 1, 01.01.1998, p. 317-323.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas

T2 - An Eastern Cooperative Oncology Group Study

AU - Hoffman, John P.

AU - Lipsitz, Stuart

AU - Pisansky, Thomas

AU - Weese, James L.

AU - Solin, Lawrence

AU - Benson, Al B.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Purpose: A prospective, multiinstitutional trial was initiated in 1991 to examine the tolerance to and efficacy of a program of preoperative chemotherapy (CTRT) and surgical resection for patients with localized adenocarcinoma of the pancreas. Patients and Methods: Fifty-three patients were assessable for analysis, with a median follow-up of 52 months for survivors. Radiation therapy (RT) totaling 5,040 cGy in 180 cGy fractions with mitomycin 10 mg/m2 day 2 and flourouracil (5-FU) 1,000 mg/m2/d continuous infusion days 2 through 5 and 29 through 32 were given as preoperative adjuvant therapy. Twelve patients did not proceed to surgery (one death, one toxicity, three local progression, six distant metastases, one intercurrent illness), whereas 41 patients underwent surgery. Of these, 17 patients did not have resection (11, hepatic and/or peritoneal metastases and six local extension that precluded resection). Twenty-four patients had tumor resection (19 Whipple, four total pancreatectomy, one distal pancreatectomy). Results: Treatment toxicity was primarily hematologic, although a comparable number suffered biliary tract complications, either from obstruction or cholangitis as a result of an occluded stent or the primary tumor. There was one postoperative death. Median survival for the entire group and for the 24 patients with resection was 9.7 and 15.7 months. This survival rate reflected the advanced state of most resected cancers (positive peritoneal cytology, three patients; margins within 2 mm, 13 patients; involved lymph nodes, four patients; and need for superior mesenteric vein (SMV) resection, four patients). Tumor progression was most frequent at metastatic sites. Conclusion: This preoperative CTRT protocol was feasible and safe in a cooperative group setting. Entry of patients with advanced tumors probably accounted for the suboptimal resectability and survival results.

AB - Purpose: A prospective, multiinstitutional trial was initiated in 1991 to examine the tolerance to and efficacy of a program of preoperative chemotherapy (CTRT) and surgical resection for patients with localized adenocarcinoma of the pancreas. Patients and Methods: Fifty-three patients were assessable for analysis, with a median follow-up of 52 months for survivors. Radiation therapy (RT) totaling 5,040 cGy in 180 cGy fractions with mitomycin 10 mg/m2 day 2 and flourouracil (5-FU) 1,000 mg/m2/d continuous infusion days 2 through 5 and 29 through 32 were given as preoperative adjuvant therapy. Twelve patients did not proceed to surgery (one death, one toxicity, three local progression, six distant metastases, one intercurrent illness), whereas 41 patients underwent surgery. Of these, 17 patients did not have resection (11, hepatic and/or peritoneal metastases and six local extension that precluded resection). Twenty-four patients had tumor resection (19 Whipple, four total pancreatectomy, one distal pancreatectomy). Results: Treatment toxicity was primarily hematologic, although a comparable number suffered biliary tract complications, either from obstruction or cholangitis as a result of an occluded stent or the primary tumor. There was one postoperative death. Median survival for the entire group and for the 24 patients with resection was 9.7 and 15.7 months. This survival rate reflected the advanced state of most resected cancers (positive peritoneal cytology, three patients; margins within 2 mm, 13 patients; involved lymph nodes, four patients; and need for superior mesenteric vein (SMV) resection, four patients). Tumor progression was most frequent at metastatic sites. Conclusion: This preoperative CTRT protocol was feasible and safe in a cooperative group setting. Entry of patients with advanced tumors probably accounted for the suboptimal resectability and survival results.

UR - http://www.scopus.com/inward/record.url?scp=0031972708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031972708&partnerID=8YFLogxK

U2 - 10.1200/JCO.1998.16.1.317

DO - 10.1200/JCO.1998.16.1.317

M3 - Article

C2 - 9440759

AN - SCOPUS:0031972708

VL - 16

SP - 317

EP - 323

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -